ArticleDiabetologia2025
Evaluating the role of alpha cell dysregulation in the progression to type 2 diabetes using mathematical simulations.
Article in Diabetologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Loss of Slc39a5 in α-cells impairs glucose metabolism by chronically increasing glucagon.Journal of advanced research · 2026Article
- Association between sleep disorders and alterations in glucose metabolism, insulin, and glucagon in patients with type 2 diabetes.Medicine · 2026Observational
- Low-normal FT4 in early pregnancy as an independent risk factor for GDM: a large-scale retrospective cohort study.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
aims/hypothesisAlpha cell dysregulation is an integral part of type 2 diabetes pathophysiology, increasing fasting as well as postprandial glucose concentrations. Alpha cell dysregulation occurs in tandem with the development of insulin resistance and changes in beta cell function. Our aim was to investigate, using mathematical modelling, the role of alpha cell dysregulation in beta cell compensatory insulin secretion and subsequent failure in the progression from normoglycaemia to type 2 diabetes defined by ADA criteria.
methodsWe developed a physiological model of glucose homeostasis, whereby the fast dynamics of glucose, insulin and glucagon are coupled to the dynamics of beta cell functional mass (a product of individual beta cell functional capacity and mass). Beta cell functional mass exhibits an initial compensatory increase in response to hyperglycaemia, followed by an eventual decline due to glucotoxicity. Alpha cell dysregulation, defined as increased glucagon secretion and lowered glucagon suppression resulting in hyperglycaemia, was introduced to varying extents, and simulations were carried out to assess the effects on beta cell functional mass over a 20 year period.
resultsThe simulations were carried out under conditions of moderate, mild or no alpha cell dysregulation. The parameters representing insulin resistance, glucagon secretion and suppression for an individual with normoglycaemia obtained from previously published work were evolved over a period of 20 years to the mean values observed in type 2 diabetes. The model was validated by visually matching the beta cell functional mass obtained from the simulations of the disease progression model to previously published parameters. Those parameters were obtained from fits of a model of OGTTs to data from a cross-sectional cohort that spanned the spectrum from normoglycaemia to type 2 diabetes. We found that mild alpha cell dysregulation elicited robust beta cell compensation, resulting in controlled postprandial glucose excursions despite the development of insulin resistance. Moderate alpha cell dysregulation initially enhanced compensation but eventually accelerated the progression to type 2 diabetes. Alpha cell dysregulation impacted the time course of the standard markers of diabetes (fasting glucose, 2 h plasma glucose and HbA CONCLUSIONS/
interpretationThe early stages of alpha cell dysregulation led to robust beta cell functional mass compensation driven by elevated fasting glucose. When the dysregulation progressed further, glucose levels rose to levels of glucotoxicity, exacerbating beta cell functional mass loss and accelerating the onset of type 2 diabetes. The various markers of diabetes (fasting glucose, 2 h plasma glucose and HbA
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.